Tuesday January 8, 2013 0 commentsCASTLE ROCK - Venaxis Inc. (Nasdaq: APPY), an in-vitro diagnostic company, has fulfilled the requirements for CE Marking in Europe for its APPY1 blood-based appendicitis test, the company announced.
Initial commercialization in Europe is planned to commence in the first quarter of 2013 in key European territories that include the UK, Italy, France, Germany and the Benalux countries, Venaxis said.
The company said it expects to announce agreements with top EU distributors beginning in the first quarter of 2013.
"We are pleased to report this important accomplishment, which allows us to market APPY1 in Europe and initiate the next critical phase of our market development effort," said Steve Lundy, Venaxis president and CEO.
"Our strategy is to leverage the experience of these key opinion leader hospital sites over the first half of 2013 in order to generate meaningful, multinational data for APPY1 that will allow us to refine our approach to the broader EU market and prepare for a full-scale launch later in 2013."
Venaxis was formerly known as AspenBio Pharma before changing its name last year. For more information, visit www.venaxis.com.